同仁堂国药(3613.HK):下半年收入明显回升 看好25年持续恢复

中信建投证券
07 May

核心观点公司24 年H2 实现营业收入、归母净利润分别为9.43 亿港元、2.80 亿港元,分别同比增长32.32%、2.24%,业绩增速在下半年明显回升,主要由于公司积极加强营销推广、叠加核心产品安宫牛黄丸提价推动香港地区收入实现明显回升,业绩符合预期。展望25 年,公司将持续调整恢复、推进降本增效,在香港及其它地区积极开设新零售终端,同时加强境外产品注册以及销售渠道的拓展,叠加积极培育新产品及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10